source
- Taiho and Cullinan’s zipalertinib shows progression‑free survival benefit in Phase 3 NSCLC trialTaiho Pharmaceutical and Cullinan Therapeutics reported that their EGFR inhibitor zipalertinib, combined with chemotherapy, significantly extended progression‑free survival for patients with advanc…
- FDA schedules hearing on Concerta generic withdrawal as Ivonescimab secures first-line lung cancer indication in ChinaThe U.S. Food and Drug Administration has granted a hearing to consider the withdrawal of a generic version of Concerta. The hearing will address regulatory concerns surrounding the product. In Ch…